Amylyx Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Amylyx Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Amylyx Pharmaceuticals Inc recorded a cumulative net loss of $-152 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -48.72%.

However, within the Healthcare sector 557 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3937, from total ROA ranking in the first quarter of 2026 at 4610.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	39 %	34.09 %	72 %	43.97 %	-42.53 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-152	-150	-145	-149	-188
Return On Assets (TTM)	-48.72 %	-51.13 %	-52.64 %	-62.17 %	-88.16 %
AMLX's Total Ranking	# 3937	# 4610	# 4141	# 4385	# 4462
Total Assets (TTM) in million	265	294	333	358	190
Seq. Total Assets Change	-9.89 %	-11.74 %	-7.03 %	87.97 %	-13.07 %
Seq. Net Income Change	-	-	-	-	-

AMLX's 5 Years Annual ROA >> Back to AMLX Management Effectiveness >> Compare AMLX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 239
Sector	# 558
Overall	# 3878

Return On Assets Statistics
High	Average	Low
10.68 %	-49.59 %	-101.09 %
(Dec 31 2023)		(Dec 31 2024)

Financial Statements
Amylyx Pharmaceuticals Inc 's Assets	$ 265 million	AMLX's Balance sheet
Amylyx Pharmaceuticals Inc 's Income	$ -43 million	Quarterly AMLX's Income Statement
AMLX's Income by Division		See AMLX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	FY
Y / Y Total Assets Change	72 %	-62.47 %	33.25 %	-	-
Total Assets in million	333	193	515	387	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-145	-302	49	-198	0
Annual Return On Assets	-43.51 %	-156.03 %	9.56 %	-51.29 %	-

AMLX's 5 Years Annual ROA >> Back to AMLX Management Effectiveness >> Compare AMLX ROA to its Competitors

More Return On Assets Ratios
AMLX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AMLX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AMLX's Competitors
Subscribers only: Roa for Amylyx Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for AMLX's Customers

You may also want to know
AMLX's Roi	AMLX's Inventory Turnover Ratio	AMLX's Growth Rates	AMLX's Dividend Comparisons
	AMLX's Profitability Ratios	AMLX's Asset Turnover Ratio	AMLX's Dividend Growth
AMLX's Roe	AMLX's Valuation Ratios	AMLX's Financial Strength Ratios	AMLX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T01:08:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.